Alzprotect’s therapeutic strategy focuses on tauopathies: Progressive Supranuclear Palsy and Alzheimer’s disease.
Three molecules are currently being developed. The most advanced of them, AZP2006, offers great therapeutic potential and was already granted the orphan drug designation in both Europe (EMA) and the United States (FDA).



Phase 1

Phase 2

Phase 3


Learn more about AZP2006